Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDX3-213B is a potent oxidative phosphorylation (OXPHOS) complex I (also known as NDUFS7) antagonist (IC50 = 3.6 nM). DX3-213B impairs ATP generation (IC50 = 11 nM) and inhibits the proliferation of MIA PaCa-2 cells (IC50 = 9 nM) in galactose-containing media. In vivo, DX3-213B significantly delays tumor growth in a syngeneic mouse model of pancreatic cancer. DX3-213B is orally bioavailable.
Sold under license from the University of Michigan
M. Wt | 478.57 |
Formula | C20H28F2N2O5S2 |
Storage | Store at -20°C |
Purity | ≥97% (HPLC) |
CAS Number | 2749555-66-4 |
PubChem ID | 162365370 |
InChI Key | HLSJMSNPBRGRGL-MRXNPFEDSA-N |
Smiles | O=S(N1C[C@H](C(N2CCC(CC2)(F)F)=O)CCC1)(C3=CC=C(S(C(C)C)(=O)=O)C=C3)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 23.93 | 50 |
The following data is based on the product molecular weight 478.57. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 4.18 mL | 20.9 mL | 41.79 mL |
2.5 mM | 0.84 mL | 4.18 mL | 8.36 mL |
5 mM | 0.42 mL | 2.09 mL | 4.18 mL |
25 mM | 0.08 mL | 0.42 mL | 0.84 mL |
References are publications that support the biological activity of the product.
Xu et al (2023) First-in-class NADH/Ubiquinone oxidoreductase core subunit S7 (NDUFS7) antagonist for the treatment of pancreatic cancer. ACS Pharmacol.Transl.Sci. 6 1164 PMID: 37588763
Xue et al (2022) Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer. J.Med.Chem. 65 3404 PMID: 35167303
If you know of a relevant reference for DX3-213B, please let us know.
Keywords: DX3-213B, DX3-213B supplier, OXPHOS, potent, orally, bioavailable, complex, 1, antogonist, oxidative, phosphorylation, pancreatic, cancer, in, vivo, NDUFS7, Oxidative, Phosphorylation, 8070, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for DX3-213B. Do you know of a great paper that uses DX3-213B from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review DX3-213B and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including: